Attribute and unit mapping
Separate genome titer, particle-associated measurements, functional activity and cellular VCN across the relevant process stages.
Scientific advisory / LVV
Lentiviral vector analytics
Connect vector production and gene-modified cell products to measurements that answer the right biological question.
The analytical question
Define what the result means.
A lentiviral vector preparation and a population of transduced cells require different analytical evidence. We help define the measurand, sample, reporting unit and decision before selecting a method. The resulting strategy connects molecular measurements with functional studies and the wider product control strategy.
- RNA genome titerA measurement of assay-detectable vector RNA, commonly reported as RNA copies per volume. Extraction, reverse transcription, DNA contamination and target accessibility can affect the result.
- Functional or transducing titerA cell-based readout of productive transduction under specified assay conditions. Cell susceptibility, endpoint and study design influence the reported result; RNA copies and particle markers are not substitutes.
- Cellular vector copy number (VCN)A cellular DNA measurement normalized to a defined denominator. Average copies per total cell and copies per transduced cell are different. Evidence must address nonintegrated DNA before a result is described as integrated VCN.
Potential workstreams
How we can help.
The final scope is agreed for the product, development stage and scientific decision.
Assay architecture and controls
Review target placement, RNA/DNA specificity, extraction recovery, reverse transcription, inhibition and reference-material suitability.
Cell-product characterization
Plan VCN normalization and, where relevant, integration-site profiling with explicit sampling, detection and interpretation limits.
Impurity and safety strategy
Map residual nucleic acids, process impurities and replication-competent lentivirus testing to distinct, appropriately scoped work packages.
Stability and comparability
Select complementary readouts to investigate change over time or after a process change, without assuming that titer alone captures product quality.
Technical data review
Assess assay assumptions, conflicting readouts and evidence gaps; prioritize additional experiments with the executing laboratory.
Consulting deliverables
What you receive.
Depending on the agreed engagement, outputs can include:
- A measurand, sample and reporting-unit map
- An assay and control matrix with documented rationale
- A VCN interpretation and normalization review
- A prioritized method-development or troubleshooting plan
- A brief for separately commissioned laboratory studies
These are proposed advisory outputs, not claims of completed experiments or validated performance. Laboratory execution and provider responsibilities are scoped separately.
Scientific boundaries
Detection of a vector sequence by PCR does not, by itself, demonstrate integration, functional transduction or the absence of replication-competent virus. Integration-site profiling and replication-competent lentivirus testing are distinct applications requiring their own evidence.
Common questions
Is VCN the same as vector titer?
No. VCN describes vector copies in a defined cell population. Vector-stock titer describes a property of the vector preparation, such as assay-detectable genomes or transducing activity per volume.
Can a molecular assay replace functional characterization?
A molecular assay can provide an informative component of a control strategy. It does not automatically replace a product-relevant functional assay or a separately justified potency strategy.
Selected references
These sources inform the scientific principles. They do not establish company credentials or endorse Genometrion.
- FDA — CMC information for human gene therapy INDs
- Geraerts et al. — Comparison of lentiviral vector titration methods
- NIST — Gene Delivery Systems
Editorial review: 31 October 2026.
Related services
Start with the question
Complex therapies.
Clearer analytical decisions.
Define the scientific question behind your project. We can discuss the evidence, methods and practical next steps.
Scientific enquiries
Let’s talk about your project.
A brief, nonconfidential outline is a useful starting point.
contact@genometrion.comEmail GenometrionOpens your email application. Contact details and enquiry guidance.